| Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review NA Molodecky, S Soon, DM Rabi, WA Ghali, M Ferris, G Chernoff, ... Gastroenterology 142 (1), 46-54. e42, 2012 | 6239 | 2012 |
| Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies SC Ng, HY Shi, N Hamidi, FE Underwood, W Tang, EI Benchimol, ... The Lancet 390 (10114), 2769-2778, 2017 | 5782 | 2017 |
| Ustekinumab as induction and maintenance therapy for Crohn’s disease BG Feagan, WJ Sandborn, C Gasink, D Jacobstein, Y Lang, JR Friedman, ... New England journal of medicine 375 (20), 1946-1960, 2016 | 1886 | 2016 |
| Ustekinumab induction and maintenance therapy in refractory Crohn's disease WJ Sandborn, C Gasink, LL Gao, MA Blank, J Johanns, C Guzzo, ... New England Journal of Medicine 367 (16), 1519-1528, 2012 | 1284 | 2012 |
| Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis R Panaccione, S Ghosh, S Middleton, JR Márquez, BB Scott, L Flint, ... Gastroenterology 146 (2), 392-400. e3, 2014 | 1109 | 2014 |
| Natalizumab for active Crohn's disease S Ghosh, E Goldin, FH Gordon, HA Malchow, J Rask-Madsen, ... New England Journal of Medicine 348 (1), 24-32, 2003 | 1007 | 2003 |
| Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies AD Frolkis, J Dykeman, ME Negrón, J Debruyn, N Jette, KM Fiest, ... Gastroenterology 145 (5), 996-1006, 2013 | 933 | 2013 |
| Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis WJ Sandborn, S Ghosh, J Panes, I Vranic, C Su, S Rousell, ... New England Journal of Medicine 367 (7), 616-624, 2012 | 926 | 2012 |
| European evidence-based consensus on the management of ulcerative colitis: current management SPL Travis, EF Stange, M Lémann, T Øresland, WA Bemelman, ... Journal of Crohn's and Colitis 2 (1), 24-62, 2008 | 738 | 2008 |
| The global incidence of appendicitis: a systematic review of population-based studies M Ferris, S Quan, BS Kaplan, N Molodecky, CG Ball, GW Chernoff, ... Annals of surgery 266 (2), 237-241, 2017 | 715 | 2017 |
| Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain A Akbar, Y Yiangou, P Facer, JRF Walters, P Anand, S Ghosh Gut 57 (7), 923-929, 2008 | 666 | 2008 |
| Ozanimod induction and maintenance treatment for ulcerative colitis WJ Sandborn, BG Feagan, DC Wolf, G D’Haens, S Vermeire, SB Hanauer, ... New England Journal of Medicine 374 (18), 1754-1762, 2016 | 503 | 2016 |
| NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis SA Hirota, J Ng, A Lueng, M Khajah, K Parhar, Y Li, V Lam, MS Potentier, ... Inflammatory bowel diseases 17 (6), 1359-1372, 2011 | 502 | 2011 |
| Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial CSJ Probert, SD Hearing, S Schreiber, T Kühbacher, S Ghosh, IDR Arnott, ... Gut 52 (7), 998-1002, 2003 | 470 | 2003 |
| Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease DA van Heel, S Ghosh, M Butler, KA Hunt, AMC Lundberg, T Ahmad, ... The Lancet 365 (9473), 1794-1796, 2005 | 409 | 2005 |
| Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey S Ghosh, R Mitchell Journal of Crohn's and Colitis 1 (1), 10-20, 2007 | 407 | 2007 |
| Inflammatory bowel disease: a Canadian burden of illness review A Rocchi, EI Benchimol, CN Bernstein, A Bitton, B Feagan, R Panaccione, ... Canadian Journal of Gastroenterology and Hepatology 26 (11), 811-817, 2012 | 389 | 2012 |
| The inflammatory bowel diseases and ambient air pollution: a novel association GG Kaplan, J Hubbard, J Korzenik, BE Sands, R Panaccione, S Ghosh, ... Official journal of the American College of Gastroenterology| ACG 105 (11 …, 2010 | 363 | 2010 |
| A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease WJ Sandborn, S Ghosh, J Panes, I Vranic, W Wang, W Niezychowski, ... Clinical gastroenterology and hepatology 12 (9), 1485-1493. e2, 2014 | 344 | 2014 |
| Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis S Ghosh, S Cowen, WJ Hannan, A Ferguson Gastroenterology 107 (4), 1031-1039, 1994 | 330 | 1994 |
Gilaad G KaplanProfessor, University of Calgary確認したメール アドレス: ucalgary.ca